Assessed for Eligibility (N = 75)

Excluded
- Not meeting inclusion criteria (N = 45)
- Declined to participate (N = 16)
- Other reasons (N = 2)

Randomized (N = 12)

Allocated to 17-hydroxyprogesterone caproate (N = 4)
All participants received allocated intervention

Allocated to Placebo (N = 8)
All participants received allocated intervention

Follow-Up
Received all planned doses (N = 3)
Discontinued because of FDA Hold (N = 1)

Follow-Up
Received all planned doses (N = 7)
Discontinued because of FDA Hold (N = 1)

Analysis
All were followed through delivery of mother and discharge of infant.
Analyzed (N = 4)

Analysis
All were followed through delivery of mother and discharge of infant.
Analyzed (N = 8)